Table 3 Best Response to PLD Therapy
From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Best Response | All Patients N = 125 | Patients with Prior Anthracycline Therapy N = 70 | Response by Line of Treatment | |
|---|---|---|---|---|
1st/2nd Line | ≥ 3rd Line | |||
N = 65 | N = 58 | |||
No. Patients (%) | ||||
Complete response | 6 (4.8) | 2 (2.9) | 4 (6.2) | 2 (3.4) |
Partial response | 47 (37.6) | 22 (31.4) | 27 (41.5) | 19 (32.8) |
Stable disease | 37 (29.6) | 25 (35.7) | 15 (23.1) | 22 (37.9) |
Progressive disease | 28 (22.4) | 17 (24.3) | 18 (27.7) | 10 (17.2) |
Not determined | 7 (5.6) | 4 (5.7) | 1 (1.5) | 5(8.6) |